Title |
Cancer Drugs Active Against Stress Signaling Pathways
|
Institution |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR, HOUSTON, TX
|
Principal Investigator |
POWIS, GARTH
|
NCI Program Director |
Suzanne ForrySchaudies
|
Cancer Activity |
Biochemistry and Pharmacology
|
Division |
DCTD
|
Funded Amount |
$1,084,734
|
Project Dates |
08/06/1990 - 04/30/2010
|
Fiscal Year |
2008
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Aging (5.0%)
Cancer (100.0%)
Chemotherapy (50.0%)
Digestive Diseases (30.0%)
Hematology (15.0%)
Metastasis (5.0%)
|
Breast Cancer (15.0%)
Colon/Rectum (15.0%)
Kidney Cancer (10.0%)
Kidney Disease (10.0%)
Ovarian Cancer (15.0%)
Pancreas (15.0%)
Prostate (15.0%)
Leukemia (15.0%)
|
Research Type |
Systemic Therapies - Discovery and Development
|
Abstract |
DESCRIPTION (provided by applicant): The scope of this Core is to provide unique and innovative capabilities for the design and highaffinity, selective and drug-like compounds against the proposed targets. Bridging several disciplines within our NCDDG program, and collaborating closely with Projects 1 to 4 and the Chemistry Core, we will bring unique capabilities to the lead identification and optimization processes by combining structure-based design and our innovative NMR-based techniques, The specific tasks can be summarized as follows: 1) to provide support to Projects 1 to 4 in the identification of lead compounds by using molecular modeling and NMR-based techniques; 2) to provide support to Projects 1 to 4, in close collaboration with the Chemistry Core, to design optimized, high-affinity, selective and drug-like compounds by using a combination of molecular modeling and NMR-based straegies.
Given our demonstrated experience with the proposed approaches and the synergy with Projects 1 to 4 and the Chemistry Core, we are confident that our efforts wil result in the identification of several lead compounds for all the proposed targets. |